november AG
november AG english
november AG reaches targets
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
november AG reaches targets
november AG has achieved its operative and strategic goals for 2002. Bristol-
Myers Squibb became the first reference customer for november’s product security
systems in the important pharma sector. Decisive progress was also made in the
development of the mini-lab for near-patient DNA analytics. Now, in the
beginning of 2003, a first prototype of the analytical unit was finished, which
integrates all steps from sample preparation to detection. The focusing on near-
market products and developments has also been consistently continued. The
therapy division had been restructured and, after good progress towards clinical
trials, was spun off in February 2003. In this process, november AG was granted
rights to participate in the new company, to expand this participation, and to
receive a special share in profit.
The consolidated net loss in 2002 amounted to 5.9 million EUR and is
significantly lower than last year’s figure (7.1 million EUR). EPS according to
IAS (loss per share) correspondingly amounts to -0.87 EUR. Discounting
restructuring costs, the consolidated net loss would amount to 5.1 million EUR
with a corresponding EPS of -0.75 EUR. Thus, the EPS lies within the previously
communicated range of -0.75 to -0.90 EUR. Consolidated revenues amounted to
3.855 million EUR (2001: 3.7 million EUR). On an adjusted basis, e.g. without
the revenues of the la fontaine companies which were deconsolidated as of
5/31/2001, an even better sales grow of 21% was achieved. In 2002, R&D costs
were expanded according to plan to 6.2 million EUR (2001: 5.2 million EUR),
while the average number of employees, adjusted to FTE, grew from 80 to 88.
Personnel expenses grew from 4.5 million EUR to 5.1 million EUR. The
consolidated operating loss (EBIT) amounted to 9.7 million EUR (2001: 8,6
million EUR). As of 12/31/2002, the balance sheet total amounted to 29.6 million
EUR (2001: 35.0 million EUR) with a total shareholders’ equity of 26.1 million
EUR (2001: 32.0 million EUR). The equity ratio thus is 88% (2001: 92%). At the
end of 2002, the total short and medium term liquidity amounted to 15.9 million
EUR (2001: 24.1 million EUR). The management believes that this will be
sufficient to reach break-even on the company level according to plan on the
basis of last and this year’s restructuring measures.
november AG, Dr. Peer N. Schröder
+49 9131 75088868, schroeder@november.de
end of ad-hoc-announcement (c)DGAP 24.03.2003
——————————————————————————–
WKN: 676290; ISIN: DE0006762909; Index:
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-
Bremen, Düsseldorf, Hannover, München und Stuttgart
240830 Mär 03
Latest News
Latest Reports
Upcoming Events
No Events found
Webcasts
No Webcasts found